The study was led by PhD student Maria Östman of the University of Oslo and colleagues, who exploited one of the fastest and most complete vaccine introductions in Europe as a natural experiment. When Norway added the monovalent Rotarix vaccine to its national childhood immunisation programme in September 2014, uptake among infants reached 92.8 percent within a short period. That near-total and abrupt shift created a clean dividing line in the population: children born before the introduction had essentially no rotavirus vaccination in infancy, while those born after it were overwhelmingly vaccinated. Such a sharp exposure boundary is rare in epidemiology, and it allowed the researchers to compare diabetes incidence across birth cohorts with unusual clarity.

Rotavirus is a highly common virus transmitted by the faecal–oral route and a leading cause of severe gastroenteritis in young children, particularly those under five years of age. Immunity builds with each infection, so repeat infections tend to be milder, but first infections can be dangerous. Rotavirus vaccines, which are oral live-attenuated products made from a laboratory-weakened virus, have dramatically reduced hospitalisation and mortality from severe rotavirus disease worldwide. Because viral infections have long been suspected of influencing the risk of type 1 diabetes — an autoimmune disease in which the immune system destroys the insulin-producing beta cells of the pancreas — researchers have debated whether rotavirus vaccination might either raise or lower diabetes risk. Previous studies in other countries have produced conflicting results, with some suggesting a protective effect and others finding no association.

To resolve the question in the Norwegian setting, the researchers followed all children born in Norway between 2007 and 2019, a total of 740,744 children, from the age of six months to five years. Crucially, they ensured that the length of follow-up was identical for children born before and after the vaccine’s introduction, eliminating a common source of bias in cohort comparisons. Data collection continued until 31 December 2024. Among the full cohort, 846 children were diagnosed with type 1 diabetes before their fifth birthday. The researchers then applied an interrupted time series analysis, a statistical technique that uses the observed pre-vaccination trend to predict what incidence would have been without the intervention, and compares that prediction with the actual observed trend afterwards.

The main analysis showed a relative increase of 11 percent in type 1 diabetes incidence among children born after the vaccine’s introduction compared with the predicted trend. In a separate adjusted analysis, the relative hazard ratio for children fully vaccinated with two doses of the monovalent vaccine, compared with unvaccinated children, was 1.17 — an apparent elevation that, however, did not reach statistical significance. The authors summarised their central finding bluntly: the study found no evidence for a reduced risk of type 1 diabetes after the introduction of rotavirus vaccination in infancy, but instead found that incidence before age five increased after vaccination was introduced. Taken at face value, that combination of results could have fuelled concerns about the vaccine’s safety.

It is here that the study’s secondary analyses become decisive. To test whether the observed increase was genuinely attributable to the rotavirus vaccine, the researchers examined what happened to diabetes incidence after other, unrelated changes to the Norwegian immunisation programme. These served as negative controls: there is no biological or epidemiological evidence that the introduction of the hepatitis B vaccine in 2016, or the switch from the 7-valent to the 13-valent pneumococcal vaccine in 2011, would affect type 1 diabetes risk. If the association seen after the rotavirus rollout reflected a true vaccine effect, similar associations should not appear around these unrelated programme changes. Yet they did. The incidence of type 1 diabetes among children born after the hepatitis B vaccine’s introduction rose by a magnitude similar to that seen after the rotavirus rollout, and the same pattern followed the pneumococcal vaccine switch.

The authors interpret this convergence as strong evidence that the initial 11 percent finding is probably not related to the rotavirus vaccine at all, but rather to other, as yet unknown changes in the environment affecting Norwegian children. Type 1 diabetes incidence has generally been increasing over recent decades, with year-to-year fluctuation, and the researchers emphasise that they do not believe any of the changes in the national vaccination programme, individually or in combination, explain the rise. As they put it, despite their best efforts to design the study to remove the influence of other unknown factors, the identical pattern appearing around every programme change — including changes hypothesised to have opposite or null effects — points to unidentified environmental factors operating across the period.

The team also systematically considered alternative explanations for the observed increase. The COVID-19 pandemic, which was followed in many countries by a temporary surge in paediatric type 1 diabetes diagnoses, was one candidate; Norway itself experienced a temporary increase in incidence in 2022 followed by a decrease. However, a recent study of Swedish and Norwegian adolescents found no increase in type 1 diabetes incidence after COVID-19 infection, weakening that hypothesis. The researchers also examined a change in Norwegian prenatal care guidelines in June 2018, which began recommending measurement of serum ferritin concentration in the first trimester of pregnancy to determine the need for iron supplementation, replacing the less sensitive measurement of haemoglobin at week 30. Because high iron levels have been suspected of association with type 1 diabetes, the change warranted scrutiny. The authors concluded it was unlikely to be relevant, noting that iron levels are usually low in pregnancy and that only children born in 2019 within the study window were affected by the new recommendations.

The authors are careful about the limits of their conclusions. They state that they do not believe rotavirus vaccination increases the risk of type 1 diabetes, but they also argue that additional studies of rotavirus vaccination and type 1 diabetes are needed in different settings and with different vaccines before any definitive conclusion is drawn. This matters because vaccine formulations differ across countries: Norway and the United Kingdom use the monovalent Rotarix vaccine alone, Germany and Italy use both Rotarix and the pentavalent RotaTeq vaccine, while Finland and Iceland implemented RotaTeq alone. Replication across these different exposure profiles would help determine whether the Norwegian findings hold elsewhere or are artefacts of local circumstances. The authors also stress the broader need for research into other environmental factors that could be associated with type 1 diabetes, given that the disease’s incidence continues to climb in many populations without a fully established cause.

For the public, the practical message is one of reassurance grounded in methodological rigour. Rotavirus vaccination has efficiently reduced hospitalisation and mortality from severe rotavirus infections in children, and the Norwegian data, once subjected to negative-control scrutiny, do not support the idea that the vaccine drives diabetes risk in early childhood. The study instead illustrates a subtle pitfall of interrupted time series designs: when a long-running upward trend in a disease coincides with a policy change, the change can appear causal even when it is not. By testing the same pattern against interventions with no plausible link to diabetes, the Oslo team showed that the 11 percent rise was more plausibly a marker of some other environmental shift affecting children born from September 2014 onward. The authors declare no conflict of interest, and their work stands as a model of how vaccine safety signals should be interrogated — thoroughly, transparently, and with controls designed to catch spurious associations before they harden into public fear.

Subject of Research: Association between rotavirus vaccination and type 1 diabetes incidence in Norwegian children

Article Title: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause

Article References: Nationwide study in Norway shows a relative 11% increase in incidence of type 1 diabetes in children aged 0.5 to 5 years after nationwide introduction of rotavirus vaccine, but secondary analyses suggest vaccine probably not the cause. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: type 1 diabetes, rotavirus vaccine, Rotarix, Norway, EASD, Diabetologia, interrupted time series, childhood immunisation, epidemiology, negative controls, autoimmune disease, vaccine safety